# Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

> **NCT00598806** · PHASE3 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 812 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Apaziquone
- **DRUG:** Placebo
- **PROCEDURE:** TURBT

## Key facts

- **NCT ID:** NCT00598806
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 812 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00598806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00598806, "Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00598806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*